share_log

三葉草生物-B：截至2024年5月31日止月份股份發行人的證券變動月報表

CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended May 31, 2024

Hong Kong Stock Exchange ·  Jun 4 14:27
Summary by Futu AI
三葉草生物製藥有限公司（「三叶草生物-B」）於2024年6月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內均無變動，維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元。此外，公司的股份期權計劃包括首次公開發售前後的購股權計劃，其中首次公開發售前購股權計劃於2021年4月15日通過，首次公開發售後購股權計劃則於2021年9月26日通過。報告期內，首次公開發售前購股權計劃的股份期權結存數目為1,854,317股，而首次公開發售後購股權計劃的股份期權結存數目為28,462,004股，但本月內均無行使期權發行新股份。報告亦確認，所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
三葉草生物製藥有限公司（「三叶草生物-B」）於2024年6月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內均無變動，維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元。此外，公司的股份期權計劃包括首次公開發售前後的購股權計劃，其中首次公開發售前購股權計劃於2021年4月15日通過，首次公開發售後購股權計劃則於2021年9月26日通過。報告期內，首次公開發售前購股權計劃的股份期權結存數目為1,854,317股，而首次公開發售後購股權計劃的股份期權結存數目為28,462,004股，但本月內均無行使期權發行新股份。報告亦確認，所有證券發行均已獲董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
On June 4, 2024, Three Clover Biopharmaceutical Co., Ltd. ('Three Clover Bio-B') submitted the latest monthly securities variation report to Hong Kong Exchanges and Clearing Limited, reporting the shareholding changes as of May 31, 2024. The report shows that the company's statutory/registered capital and issued shares remained unchanged during the reporting period, with a total of 2,000,000,000 shares, a face value of US$0.0001 per share, and a total amount of US$200,000. In addition, the company's share option plan includes the pre- and post-listing stock option plans, with the pre-listing stock option plan approved on April 15, 2021 and the post-listing stock option plan approved on September 26, 2021. During the reporting period, the closing balance of share options for the pre-listing...Show More
On June 4, 2024, Three Clover Biopharmaceutical Co., Ltd. ('Three Clover Bio-B') submitted the latest monthly securities variation report to Hong Kong Exchanges and Clearing Limited, reporting the shareholding changes as of May 31, 2024. The report shows that the company's statutory/registered capital and issued shares remained unchanged during the reporting period, with a total of 2,000,000,000 shares, a face value of US$0.0001 per share, and a total amount of US$200,000. In addition, the company's share option plan includes the pre- and post-listing stock option plans, with the pre-listing stock option plan approved on April 15, 2021 and the post-listing stock option plan approved on September 26, 2021. During the reporting period, the closing balance of share options for the pre-listing stock option plan was 1,854,317 shares, while the closing balance of share options for the post-listing stock option plan was 28,462,004 shares, but no options were exercised to issue new shares this month. The report also confirms that all securities issuances have been approved by the board of directors and comply with the relevant requirements of the Listing Rules of Hong Kong Exchanges and Clearing Limited.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.